Đang chuẩn bị liên kết để tải về tài liệu:
Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: A retrospective cohort analysis

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Neoadjuvant chemotherapy (NAC) is increasingly used to treat locally advanced breast cancer (LABC). Improved response to NAC correlates with better survival outcomes. | Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy A retrospective cohort analysis

TÀI LIỆU LIÊN QUAN

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: A randomized controlled trial

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: A retrospective study

Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial

CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: Study protocol of a randomized controlled trial

TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: Real-world results from a single academic center in Austria